Navigation Links
Johns Hopkins receives funding for cholera vaccine initiative
Date:12/27/2012

The Johns Hopkins Bloomberg School of Public Health was awarded a four-year, $5 million grant from the Bill & Melinda Gates Foundation to promote the effective use of oral cholera vaccine around the world. The Delivering Oral Vaccine Effectively (DOVE) program will provide relief agencies and governments with technical assistance on how to use oral cholera vaccine, evaluate current vaccine-use practices and develop new field surveillance methods for monitoring and controlling outbreaks of the disease.

Cholera is an infectious disease caused by drinking unsanitary water. The disease is estimated to be responsible for between 100,000 to 200,000 deaths worldwide each year and infects as many as 2.5 million people annually. The oral cholera vaccine is over 70 percent effective and costs $1.85 per dose, but is not yet widely used in preventing outbreaks.

"We believe this grant will greatly facilitate the appropriate use of the new cholera vaccine. In partnership with the World Health Organization, UNICEF and other national and international agencies, we believe the DOVE project will provide the knowledge, technical assistance and encouragement to bring this life-saving vaccine to those who need it most," said David Sack, MD, director of DOVE and professor in the Department of International Health at the Bloomberg School.

In addition to researching and evaluating vaccine-use practices, DOVE will establish cholera surveillance in the northern region of Cameroon near Lake Chad, which appears to be a cholera hotspot. The site will help researchers develop and study methods for detecting outbreaks in remote areas and potentially for using oral vaccine to contain the disease.

The DOVE program will be part of a network of vaccine projects funded by the Gates Foundation to prevent outbreaks of cholera worldwide.


'/>"/>

Contact: Tim Parsons
tmparson@jhsph.edu
410-955-7619
Johns Hopkins University Bloomberg School of Public Health
Source:Eurekalert

Page: 1

Related medicine news :

1. US Drug Watchdog Now Urges Loved Ones Of A Diabetic Who Died From Bladder Cancer Who Had Used The Diabetes Drug Called Actos To Call The Johnson Law Group Immediately
2. A Serious Problem: Medical Malpractice Lawyers at Console & Hollawell React to Alarming Doctor Error Statistics from Johns Hopkins University Researchers
3. US Drug Watchdog Now Fears Most Women Never Heard About Yaz or Yasmin Birth Control Pill Side Effects and They Urge to Victims to Call the Johnson Law Group-Get Help Now
4. US Drug Watchdog Now Urges Any US Citizen Who Used the Diabetes Drug Called Actos and Then Developed Bladder Cancer To Contact The Johnson Law Group For A Legal Review
5. Johns Hopkins malpractice study: Surgical never events occur at least 4,000 times per year
6. US Drug Watchdog Now Urges Yaz Yasmin Birth Control Pill Users Who Suffered a Stroke, Blood Clots, or a Heart Attack to Call the Johnson Law Group for a Legal Review
7. US Drug Watchdog Now Urges Users Of The Diabetes Drug Called Actos To Call The Johnson Law Group if They Have Developed Bladder Cancer-Time Is Of The Essence
8. Johns Hopkins to aid The Leapfrog Group in grading the safety and quality of US hospitals
9. US Drug Watchdog Now Urges Family Members Of A Diabetic Who Died From Bladder Cancer After Using The Diabetes Drug Called Actos To Call The Johnson Law Group Immediately
10. US Drug Watchdog Now Urges Yaz Yasmin Birth Control Pill Users Who Suffered a Pulmonary Embolism or a Heart Attack to Call the Johnson Law Group Now-Before Time Runs Out
11. Fasting may benefit patients with epilepsy, Johns Hopkins Childrens Center study suggests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2017)... ... August 23, 2017 , ... Earlier this month, the ... use of health IT to create efficiencies in healthcare information exchange and a trusted ... 2017 Summer Forum which featured keynote addresses by Donald W. Rucker, MD, head ...
(Date:8/23/2017)... Ogden, Utah (PRWEB) , ... August 23, 2017 , ... ... 2013. , Give Back Day is a time Nightingale College dedicates to serving ... with organizations that thrive on donations and volunteers or those that need a little ...
(Date:8/23/2017)... ... August 23, 2017 , ... Boling Vision ... home to Indiana, and is now seeing patients at Boling Vision Center’s Elkhart ... in the diagnosis and treatment of eye disease, medical retina, high-technology cataract surgery, ...
(Date:8/23/2017)... ... August 23, 2017 , ... TSC Advantage ... - for Risk Management Solution Innovations and Security Solution for Government Innovations. Both ... in 2017 and its DHS SAFETY Act-designated enterprise security assessment approach. , The ...
(Date:8/22/2017)... ... August 22, 2017 , ... The Women’s Choice Award, a growing ... Relief with the 2017 Women’s Choice Award. The identification by women of an ... of 4 migraine sufferers are women. In a survey taken by the Women’s Choice ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... Aug. 15, 2017  Axium Pharmaceuticals Inc., the creator of the drug ... in the beginning stages of an IPO. The ... with the average cost of a prescription epilepsy drug being $450.00-$1200.00 for ... AXIUM PHARMACEUTICALS, INC ... Another staggering figure is the fact that Americans spent ...
(Date:8/14/2017)... N.J. and PETACH TIKVAH, Israel ... Inc. (NASDAQ: BCLI), a leading developer of adult stem ... the second quarter ending June 30, 2017. ... stages of preparing for our pivotal Phase 3 trial ... Chaim Lebovits , President and Chief Executive Officer of ...
(Date:8/8/2017)... AVIV, Israel, Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: ... immunology, today reports its financial results for the second ... achievements during the second quarter 2017 and to date: ... multiple clinical development programs for the Company,s lead project, ... 3 pivotal study with BL-8040 as novel stem cell ...
Breaking Medicine Technology: